BridgeMD
Effects of a single denosumab injection on reduction of total contact cast treatment and consolidation of bone fractures caused by acute Charcot foot in patients with diabetes mellitus (CHARCOT study)
EU CTIS ID: 2024-518637-28-00
What this study is testing
To study treatment with denosumab, a registered injectable RANKL antibody has beneficial effects on bone fracture healing and foot deformation in diabetic subjects with a Charcot foot.Time to cession of total contact cast (Days) in combination with curation of foot fractures on X ray every month and CT scan at baseline, 3,6 and 9 months of the affected foot (by independent radiologist) upon denosumab treatment in diabetes patients with radiologically proven Charcot foot.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - Radiologically proven Charcot foot (x ray, CT or MRI) - Confirmed diagnosis of either type 1 or type 2 diabetes with neuropathy - Patient is willing and able to provide written consent - Normal life expectancy
You likely can't join if
- - Known latex allergy - Scheduled dental treatment (molar extraction) in the next year
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.